- Express Scripts Holding Co.
- Medco Health Solutions Inc.
- Pfizer Inc.
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Schering-Plough Corp.
- Novartis AG
- Amgen Inc.
- Genentech Inc.
- Chugai Pharmaceutical Co. Ltd.
- Eli Lilly & Co.
- Merck & Co. Inc.
- Boehringer Ingelheim International GmbH
- Eyetech Inc.
- Elan Corp. PLC
- Biogen Inc.
- Merck Serono SA
- NitroMed Inc.
- Gilead Sciences Inc.
- Infinity Pharmaceuticals Inc.
- Innoviva Inc.
- Pharmion Corp.
- Dynogen Pharmaceuticals Inc.
- Vela Pharmaceuticals Inc.
- King Pharmaceuticals Inc.
- Reliant Pharmaceuticals Inc.
- Pronova BioPharma ASA
- Amylin Pharmaceuticals Inc.
- Schering AG
- Sirna Therapeutics Inc.
- Alnylam Holding Co.
- Angiosyn Inc.
- Aton Pharma Inc.
- Johnson & Johnson
- Egea Biosciences Inc.
- NeoGenesis Pharmaceuticals Inc.
- Takeda California Inc.
- Lilly, Boehringer Ingelheim in duloxetine co-promotion
- Pfizer develops Eyetech's Macugen
- Biogen, Elan to co-develop and sell Antegren; deal terminated
- EyeTech Pharmaceuticals gets rights to Gilead's NX 1838
- GSK signs broad collaboration with Theravance
- Pharmion acquires Pharmacia & Upjohn's Vidaza
- Reliant licenses Pronova Biocare's Omacor
- Merck, Alnylam end RNAi agreement for ophthalmic drugs
- Pfizer buys Angiosyn in deal based largely on milestones
- Merck & Co. buys Aton Pharma
- Johnson & Johnson buys alliance partner Egea Biosciences
- Schering-Plough acquires NeoGenesis
- Takeda acquires Syrrx
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.